Totally implantable central venous access device in the treatment of patients with multi- and extensively drug-resistant tuberculosis co-infected with human immunodeficiency virus and with history of illicit drug use.

A. Skrahin (Minsk, Belarus), M. Makouski (Minsk, Belarus), D. Pechinsky (Minsk, Belarus), K. Dobysh (Minsk, Belarus), H. Hlushanina (Minsk, Belarus), A. Sinha (Minsk, Belarus), A. Skrahina (Minsk, Belarus)

Source: International Congress 2018 – Tuberculosis comorbidities

Session: Tuberculosis comorbidities
Session type: Thematic Poster
Number: 2707

Disease area: Respiratory infections

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
A. Skrahin (Minsk, Belarus), M. Makouski (Minsk, Belarus), D. Pechinsky (Minsk, Belarus), K. Dobysh (Minsk, Belarus), H. Hlushanina (Minsk, Belarus), A. Sinha (Minsk, Belarus), A. Skrahina (Minsk, Belarus). Totally implantable central venous access device in the treatment of patients with multi- and extensively drug-resistant tuberculosis co-infected with human immunodeficiency virus and with history of illicit drug use.. 2707

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Pulmonary complications in intravenous drug users with and without human immunodeficiency virus co-infection. Source: International Congress 2019 – Pleural infection and complicated pneumonia Year: 2019
The role of adherence in tuberculosis HIV-positive patients treated in ambulatory regimen Source: Eur Respir J 2003; 21: 785-788 Year: 2003
Pulmonary disorders and critical care of patients with HIV infection in the era of anti-retrovirals Source: Annual Congress 2006 - MP6 – Pulmonary disorders and critical care of patients with HIV infection in the era of anti-retrovirals Year: 2006
Experience in the use of Bedakville in the therapy of multidrug-resistant tuberculosis and HIV infection. Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis Year: 2018
Safety of the endobronchial valve use in the complex treatment of patients with destructive MDR/XDR TB associated with HIV infection. Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020
The use of totally implantable central venous access ports for the treatment of multidrug-resistant tuberculosis (MDR-TB) at the programmatic level. Prospective cohort study Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II Year: 2019
The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection Source: Eur Respir J 2015; 45: 569-571 Year: 2015
The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection Source: Eur Respir J 2015; 45: 571-574 Year: 2015
HIV co-infection excludes many drug-resistant tuberculosis patients from clinical trials with novel antituberculosis drugs Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015
Impact of adverse drug reactions on treatment interruption in TB patients with and without HIV coinfection Source: ISSN=ISSN 1810-6838, ISBN=, page=190 Year: 2006
The treatment of tuberculosis and application of HAART (highly active anti retroviral treatment) in HIV positive patients Source: Annual Congress 2005 - Challenges in the management of pulmonary tuberculosis: a continuous clinical problem Year: 2005
Comparative analysis of pneumonia in patients with drug dependence with HIV infection and without HIV. Source: Virtual Congress 2020 – Clinical challenges in pneumonia Year: 2020
Application of therapeutic pneumoperitoneum for multi-drug resistant cavitary TB in HIV – infected patients Source: Eur Respir J 2004; 24: Suppl. 48, 650s Year: 2004
The impact of bedaquiline and delamanid containing regimens on liver function in patients multi-infected with pulmonary DR-TB, HIV and viral hepatitis Source: International Congress 2019 – Tuberculosis: treatment and management Year: 2019
TB infection in children receiving genetically engineered biologic drugs Source: International Congress 2019 – Paediatric tuberculosis Year: 2019
Impact of extensive drug resistance on treatment outcomes in non-HIV infected adults with MDR-TB Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis Year: 2007
Tuberculosis in HIV-infected persons in the context of wide availability of highly active antiretroviral therapy Source: Eur Respir J 2004; 24: 11-17 Year: 2004
Challenges and perspectives for improved management of HIV/Mycobacterium tuberculosis co-infection Source: Eur Respir J 2010; 36: 1242-1247 Year: 2010
Safety of bedaquiline for treatment of MDR/XDR tuberculosis in HIV co-infected patients Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities Year: 2019
Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients Source: Eur Respir J, 55 (6) 1902383; 10.1183/13993003.02383-2019 Year: 2020